Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMET-3: AR-15512 for Dry Eye Disease
NCT05360966Phase 3Completed
- Sponsor
- Aerie Pharmaceuticals
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dry eye disease (DED) comparing 0.003% AR-15512 with Vehicle (2 arms). Primary endpoint: Percentage of Subjects Who Achieved Equal to or Greater Than 10 Millimeter Increase From Pre-drop at Baseline to Post-drop on Day 14 in Study Eye Unanesthetized Schirmer Score. Started Jul 2022; status: completed.
02
Drugs
acoltremon
03
Conditions
dry eye disease (DED)
Beyond the preview
Go deeper on NCT05360966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05360966.